Importer of Controlled Substances; Notice of Application; Mylan Technologies, Inc., 6131-6132 [2013-01835]
Download as PDF
<![CDATA[
6131
srobinson on DSK4SPTVN1PROD with
Federal Register / Vol. 78, No. 19 / Tuesday, January 29, 2013 / Notices
(‘‘the ’949 patent’’); RE 41,922 (‘‘the ’922
patent’’); 7,863,533 (‘‘the ’533 patent’’);
7,789,697 (‘‘the ’697 patent’’); 7,912,501
(‘‘the ’501 patent’’); D558,757 (‘‘the
D’757 patent’’); and D618,678 (‘‘the
D’678 patent’’) (collectively, ‘‘the
Asserted Patents’’). The complaint
further alleges the existence of a
domestic industry. The respondents
named in the Commission’s notice of
investigation are Samsung Electronics
Co, Ltd. of Korea; Samsung Electronics
America, Inc. of Ridgefield Park, New
Jersey; and Samsung
Telecommunications America, LLC of
Richardson, Texas (collectively,
‘‘Samsung’’). A Commission
investigative attorney (‘‘IA’’)
participated in the investigation.
On May 3, 2012, the ALJ issued an ID
partially terminating the investigation
with respect to all claims of the ’533
patent; claims 1–3, 11, 12, 15, 16 and
21–27 of the ’697 patent; and claim 3 of
the ’949 patent (Order No. 17) (not
reviewed by the Commission, May 3,
2012).
On October 24, 2012, the ALJ issued
his final ID in this investigation finding
a violation of section 337 in connection
with the claim of the D’678 patent;
claims 1, 4–6 and 10–20 of the ’949
patent; claims 29, 30 and 33–35 of the
’922 patent; and claims 1–4 and 8 of the
’501 patent. The ALJ found no violation
of section 337 in connection with the
claim of the D’757 patent; claims 31 and
32 of the ’922 patent; and claims 13 and
14 of the ’697 patent. The ALJ also
found that the asserted claims of the
Asserted Patents were not shown to be
invalid. The ALJ further found that a
domestic industry in the United States
exists that practices the Asserted
Patents, except for the ’697 patent. On
November 7, 2012, the ALJ issued his
recommended determination on remedy
and bonding.
Apple and Samsung filed timely
petitions for review of various portions
of the final ID, as well as timely
responses to the petitions. The IA filed
only a response to the petitions for
review. On December 3, 2012, Apple
and Samsung filed public interest
comments pursuant to Commission rule
210.50(a)(4). That same day, non-party
Google filed submissions in response to
the Notice of Request for Statements on
the Public Interest. See 77 FR 68829–30
(Nov. 16, 2012).
Having examined the record of this
investigation, including the ALJ’s final
ID, the petitions for review, and the
responses thereto, the Commission has
determined to review the final ID in its
entirety. The Commission does not seek
further briefing at this time. Rather, the
Commission remands the investigation
VerDate Mar<15>2010
16:47 Jan 28, 2013
Jkt 229001
to the ALJ with respect to certain issues
related to the ’922 patent and the ’501
patent, as set forth in the accompanying
Remand Order.
In light of the remand, the ALJ shall
set a new target date within thirty days
of this notice consistent with the
Remand Order. The current target date
for this investigation is March 27, 2013.
Briefing, if any, on remanded and
reviewed issues, and on remedy,
bonding, and the public interest will
follow Commission consideration of the
remand ID.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in
sections 210.42–46 of the Commission’s
Rules of Practice and Procedure (19 CFR
210.42–46).
By order of the Commission.
Issued: January 23, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–01771 Filed 1–28–13; 8:45 am]
BILLING CODE 7020–02–P
the federal trustees), to complete two
restoration projects selected by the
trustees valued at approximately
$800,000.00, and to reimburse the
trustees for any further monitoring or
corrective action obligations after
completion of construction of the
restoration project. The Settlement
includes a covenant not to sue under
Section 107(a) of CERCLA.
The publication of this notice opens
a period for public comment on the
consent decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
United States and State of Texas v. GB
Biosciences Corp., et al., D.J. Ref. No.
90–5–1–1–09071. All comments must be
submitted no later than thirty (30) days
after the publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
By e-mail
By mail .....
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree Under the
Comprehensive Environmental
Response, Compensation, and Liability
Act
On January 22, 2013, the Department
of Justice lodged a proposed Consent
Decree in the United States District
Court for the Southern District of Texas
in the lawsuit entitled, United States
and State of Texas v. GB Biosciences
Corp., et al., Civil Action No. 4:13–CV–
00151.
In this action the United States, on
behalf of the National Oceanic and
Atmospheric Administration (‘‘NOAA’’)
and the U.S. Department of Interior
(‘‘DOI’’), as federal trustees, together
with the State of Texas, seeks natural
resource damages pursuant to Section
107(a) of the Comprehensive
Environmental Response,
Compensation, and Liability Act
(‘‘CERCLA’’), in connection with the
Greens Bayou Site located in Houston,
Texas (the ‘‘Site’’).
The United States and the State have
negotiated a consent decree with GB
Biosciences Corp., ISK Magnetics, Inc.,
and Occidental Chemical Corp.
(collectively ‘‘Settlors’’) to resolve the
CERCLA claims, as well as the state law
claims. Under the Consent Decree, the
Settlors agree to reimburse the United
States and the State for natural resource
damage assessment costs ($31,060.00 to
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Send them to:
pubcommentees.enrd@usdoj.gov.
Assistant Attorney General
U.S. DOJ—ENRD
P.O. Box 7611,
Washington, D.C. 20044–7611.
During the public comment period,
the consent decree may be examined
and downloaded at this Justice
Department Web site: https://
www.usdoj.gov/enrd/
Consent_Decrees.html. We will provide
a paper copy of the consent decree upon
written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
Please enclose a check or money order
for $54.75 (25 cents per page
reproduction cost) payable to the United
States Treasury. For a paper copy
without the exhibits, the cost is $17.50.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2013–01761 Filed 1–28–13; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Mylan
Technologies, Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on December 7, 2012, Mylan
E:\FR\FM\29JAN1.SGM
29JAN1
6132
Federal Register / Vol. 78, No. 19 / Tuesday, January 29, 2013 / Notices
Dated: January 15, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Technologies, Inc., 110 Lake Street,
Saint Albans, Vermont 05478, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
BILLING CODE 4410–09–P
Schedule
Methylphenidate (1724) ................
Fentanyl (9801) ............................
srobinson on DSK4SPTVN1PROD with
[FR Doc. 2013–01835 Filed 1–28–13; 8:45 am]
II
II
Drug Enforcement Administration
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule II, which
falls under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 28, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedules
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
VerDate Mar<15>2010
16:47 Jan 28, 2013
Jkt 229001
DEPARTMENT OF JUSTICE
Importer of Controlled Substances;
Notice of Application; Alkermes
Gainesville, LLC
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on October 11, 2012, Alkermes
Gainesville, LLC., 1300 Gould Drive,
Gainesville, Georgia 30504, made
application to the Drug Enforcement
Administration (DEA) for registration as
an importer of noroxymorphone (9668),
a basic class of controlled substance
listed in schedule II.
The company plans to import the
listed substance for analytical research
and testing.
The import of the above listed basic
class of controlled substance will be
granted only for analytical testing and
clinical trials. This authorization does
not extend to the import of a finished
FDA approved or non-approved dosage
form for commercial distribution in the
United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C. 952
(a)(2)(B) may, in the circumstances set
forth in 21 U.S.C. 958(i), file comments
or objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 28, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: January 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–01837 Filed 1–28–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Petition
Requirements and Investigative Data
Collection: Trade Act of 1974, as
Amended
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Employment
and Training Administration (ETA)
sponsored information collection
request (ICR) revision titled, ‘‘Petition
Requirements and Investigative Data
Collection: Trade Act of 1974, as
Amended,’’ to the Office of Management
and Budget (OMB) for review and
approval for use in accordance with the
Paperwork Reduction Act (PRA) of 1995
(44 U.S.C. 3501 et seq.).
DATES: Submit comments on or before
February 28, 2013.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained from the RegInfo.gov
Web site, https://www.reginfo.gov/
public/do/PRAMain, on the day
following publication of this notice or
by contacting Michel Smyth by
telephone at 202–693–4129 (this is not
a toll-free number) or sending an email
to DOL_PRA_PUBLIC@dol.gov.
Submit comments about this request
to the Office of Information and
Regulatory Affairs, Attn: OMB Desk
Officer for DOL–ETA, Office of
Management and Budget, Room 10235,
725 17th Street NW., Washington, DC
20503, Fax: 202–395–6881 (this is not a
toll-free number), email:
OIRA_submission@omb.eop.gov.
SUMMARY:
E:\FR\FM\29JAN1.SGM
29JAN1
]]>Agencies
[Federal Register Volume 78, Number 19 (Tuesday, January 29, 2013)]
[Notices]
[Pages 6131-6132]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01835]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; Mylan
Technologies, Inc.
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on December 7, 2012, Mylan
[[Page 6132]]
Technologies, Inc., 110 Lake Street, Saint Albans, Vermont 05478, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as an importer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methylphenidate (1724)..................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
finished dosage form (FDF) from foreign sources for analytical testing
and clinical trials in which the foreign FDF will be compared to the
company's own domestically-manufactured FDF. This analysis is required
to allow the company to export domestically-manufactured FDF to foreign
markets.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedule II, which falls under the authority of
section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 28, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substances
in schedules I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: January 15, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-01835 Filed 1-28-13; 8:45 am]
BILLING CODE 4410-09-P
